Dr. Atul Kumar (group web page)
Dr. Kumar has more than twenty years of experience in synthetic organic chemistry and is involved in design and synthesis of New Chemical Entities for various therapeutic areas such as Women Reproductive Health Research (Osteoporosis),and anticancer. His expertise spans in the area of Drug Design, Green synthesis of active pharmaceutical ingredients (APIs) and intermediates. He introduced a new strategy for organic synthesis utilizing Functional Ionic Liquid and named as Functional Ionic Liquid Mediated Synthesis (FILMS) {Green Chemistry 2011, 13, 2459}. Several of his molecules are in different phases of drug development which includes, CDRI Anti-osteoporosis Drug Candidate CDRI-99/373 (CENTHANK). Which exhibits anti-osteoporotic activity better than Raloxifene (presently drug of choice for treatment of osteoporosis). Currently in phase-I Clinical Trial and approved for development in CSIR- Fast Track Translational (FTT project). Dr Kumar’s other molecules CDRI-007-1235 is a First in class drug candidate for colon cancer and leukaemia, it is currently in preclinical development. He is Global Advisor SciFinder–Chemical Abastracts Services (CAS) A division of the American Chemical Society(ACS) Columbus, OH-USA and Apex Committee, member Biotechnology Industry Research Assistance Council (BIRAC). Dr. Kumar is the recipient of prestigious awards, Organization of Pharmaceutical Producers of India (OPPI) OPPI SCIENTIST AWARD-2007, VIGYAN RATNA SAMMA 2011-12 (Council of Science and Technology,. Penta Star awards from SciFinder –Chemical Abastracts Services, A division of the American Chemical Society(ACS) Columbus, OH-USA. 2014-2015.
Dr. Gautam Panda (Group Webpage)
The contribution of Dr. Panda spans several areas of contemporary interest in synthetic organic and medicinal chemistry. Dr. Panda works in collaboration with experimental biologists, and has primarily chosen cancer and tuberculosis as his therapeutic targets. His contribution in amino acids (AA) derived pharmaceuticals (small molecules, natural products and steroidomimetics) offers an encouraging avenue for developing anti cancer agents. Chirality derived from amino acids based architectures provide new and easy to incorporate chiral chemical space which otherwise very difficult to introduce and composed of several synthetic steps for asymmetric steroids. His research on Trisubstituted methanes (TRSM) has resulted an area where significant work is currently underway in the world. One molecule (CDRI; S-006-830) has been very promising from his lab. In the last fifteen years of independent research, Dr. Panda has published 88 papers, which received around 1473 citations with h-index of 22.
Dr. Dipankar Koley (Group Webpage)
Dipankar Koley joined CSIR-CDRI as scientist in 2010. He did his master in organic chemistry from Burdwan University, West Bengal and earned Ph.D. from CSIR-IICT, Hyderabad under the supervision of Dr. Tushar Kanti Chakraborty. He then carried out his postdoctoral studies at Purdue University, USA. His research interest includes asymmetric organocatalysis, total synthesis of bioactive natural products, C‒H functionalization, design, synthesis and conformational analysis of peptides and peptidomimetics of biological importance.
Dr. Namrata Rastogi (Group Webpage)
Her group is currently working to develop novel methodologies using diazo compounds under visible light and/or metal catalysis. They are also involved to explore the behaviour of diazo compounds under visible light catalysis and to develop novel strategies for the synthesis of carbocycle and heterocycles with important medicinal activities. Their group is actively engaged in developing small molecules against leishmanial and mararial parasite based on privileged heterocyclic scaffolds.
Dr. Kishore Mohanan (Group Webpage)
Research in Dr. Kishore's group involves the development of novel strategies for the synthesis of medicinally active heterocycles. Their work is mainly focused on the applications of the well-known Bestmann-Ohira reagent in the synthesis of nitrogen heterocycles. They have recently developed an attractive protocol for the regioselective synthesis of densely functionalized pyrazoles and spiro-oxindoles-pyrazolines employing BOR as a 1,3-dipolar species in a domino-pathway. Furthermore, an efficient strategy has been uncovered demonstrating for the first time that BOR can be employed in a domino multicomponent reaction involving aldehydes and amines for the diastereoselective synthesis of 1,4,5-trisubstituted-1,2,3-triazolines.2 Moreover, a domino-HWE homologation/1,3-dipolar cycloaddition/oxidation sequence involving BOR has been disclosed for the regioselective synthesis of densely functionalzed phosphonylpyrazoles.
Dr. Pintu Mondal (Group Webpage)
Glyco-conjugates are the most functionally and structurally diverse molecules in nature and it is now well established that protein- and lipid-bound saccharides play essential roles in many molecular processes impacting eukaryotic biology and disease. Our group is addressing these issues by developing efficient methods and strategies for complex biologically relevant oligosaccharides that can be utilized for designing glyco-conjugates and vaccine designing. In particular, we have developed methods that employ a small number of monosaccharide building blocks for the assembly of the large number of complex compounds through minimal number of chemical steps. Furthermore, we have devised new approaches for controlling anomeric selectivity for stereoselective glycosylation, which represent one of the most important stumbling blocks in oligosaccharide assembly. The group is also engaged in the design and synthesis of medicinally active heterocyclic scaffolds and pharmacophores
Dr. Ajay Kumar Srivastava (Group Webpage)
Dr. Srivastava holds a master degree in Chemistry from the University of Delhi and doctorate degree in Chemistry from Jadavpur University. He has two years postdoctoral research experience in the field of Chemical-Biology with Prof. S. B. Park at Department of Chemistry, Seoul National University, South Korea. In Aug 2011, he started working as Scientist at the Medicinal Chemistry and Pharmacology Division of CSIR-Indian Institute of Chemical Technology, Hyderabad and has moved to CSIR-Central Drug Research Institute, Lucknow in March 2017. His research interest includes "i) Development of novel post-IMCR modifications for the synthesis of alkaloid mimicking polycyclic skeletons with sp3-rich character, ii) One-pot tandem protocols and asymmetric synthesis, iii) Development of focused small molecule libraries, iv) Total Synthesis